Tripodi A, Chantarangkul V, Negri B, Clerici M, Mannucci P M
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Institute of Internal Medicine, University and IRCCS Maggiore Hospital, Milano, Italy.
Thromb Haemost. 1998 Feb;79(2):439-43.
Stocks of the International Reference Preparation (IRP) for thromboplastin, human, plain, coded BCT/253 and held by the World Health Organization (WHO) are nearly exhausted and must be replaced. For practical reasons the choice of the replacement candidate was restricted to two available human recombinant preparations which were coded as X/95 and Y/95 and calibrated in an international collaborative study involving 19 laboratories from Europe, Australia, Canada and Argentina. To minimize the differences between routes of calibration, the two candidates were calibrated against the existing WHO-IRP from human, rabbit and bovine origin and the final ISI was the resultant average value. On the basis of predefined criteria (i.e., within- and between-laboratory precision of the calibration and the conformity to the calibration model), X/95 was the preferred candidate. The assigned ISI (SE of the mean) value is 0.940 (0.0060) and the interlaboratory coefficient of variation 4.7%.
世界卫生组织(WHO)持有的编码为BCT/253的人源性普通凝血活酶国际参考制剂(IRP)库存已几近耗尽,必须予以补充。出于实际原因,替代候选品的选择限于两种现有的重组人源制剂,编码分别为X/95和Y/95,并在一项有来自欧洲、澳大利亚、加拿大和阿根廷的19个实验室参与的国际协作研究中进行了校准。为尽量减少校准途径之间的差异,将这两种候选品与现有的源自人、兔和牛的WHO-IRP进行校准,最终的国际敏感度指数(ISI)为所得平均值。根据预定义标准(即校准的实验室内和实验室间精密度以及与校准模型的符合度),X/95是首选候选品。指定的ISI(均值的标准误)值为0.940(0.0060),实验室间变异系数为4.7%。